Fujian Medical University
福建医科大学
Hospitals that carry this university's name, added together, plus papers and trials that name only the university.
Research activity, not treatment quality. Not medical advice. How this works
Nasopharyngeal carcinoma
鼻咽癌Led 118 of 2,375 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (23.4%).
- Open trials led
- 5
- Research papers it led
- 118
- Trials it led
- 17
- Share of China's trials
- 2.9%
- Share of the world's papers
- 3.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Thyroid V40 is a good predictor for subclinical hypothyroidism in patients with nasopharyngeal carcinoma after intensity modulated radiation therapy: a randomized clinical trial.
- Comparison the acute toxicity of two different induction chemotherapy schedules with cisplatin and fluorouracil in nasopharyngeal carcinoma patients.
- Appraisal of Radiologic Size Criteria for Malignant Lymph Nodes in Parotid Region in Nasopharyngeal Carcinoma: Implication for Parotid-Sparing IMRT.
- Population-based nasopharyngeal carcinoma survival in southern China.
- VMAT with CCC Algorithm Optimizes Trismus Prevention: Dose-Response Analysis of Jaw Muscles Dmean and Dmax in T3-T4 Nasopharyngeal Carcinoma.
Trials on ClinicalTrials.gov6
- Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
- MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC
- IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features
- CTV Delineation Based Solely on Geometric Expansion From GTV in Nasopharyngeal Carcinoma
- Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC
- Maintenance Immunotherapy With Deferred Salvage Radiotherapy After Response to Chemoimmunotherapy in Recurrent Nasopharyngeal Carcinoma
Oesophageal squamous cell carcinoma
食管鳞状细胞癌Led 105 of 2,923 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.9%).
- Open trials led
- 5
- Research papers it led
- 105
- Trials it led
- 11
- Share of China's trials
- 1.9%
- Share of the world's papers
- 2.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Long-term outcomes of S-1-based chemoradiotherapy in inoperable elderly patients with esophageal carcinoma: A multicenter, randomized, phase III clinical trial.
- Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: Phase 2 randomized trial (REVO).
- Comparison of indocyanine green-near-infrared fluorescence guided and traditional mediastinal lymphadenectomy during radical esophagectomy: A randomized controlled trial.
- Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.
- SRRN: A regional lymph node ratio-based staging system enhancing prognostic accuracy in esophageal squamous cell carcinoma.
Trials on ClinicalTrials.gov6
- A Non-inferiority Study of Indocyanine Green-guided Sentinel Lymph Node Mapping Versus Conventional Lymph Node Dissection in Esophageal Cancer
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC
- A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
- Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC
- Postoperative Radiotherapy in Thoracic Esophageal Squamous Cell Carcinoma With Neoadjuvant Chemoradiotherapy
- SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
Hepatocellular carcinoma
肝细胞癌Led 288 of 14,765 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (5.5%).
- Open trials led
- 5
- Research papers it led
- 288
- Trials it led
- 8
- Share of China's trials
- 0.5%
- Share of the world's papers
- 1.0%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Implantable artificial lymph node enables rapid in vivo neoantigen-specific T-cell generation and expansion for improving antitumor immunity.
- 2,5-dimethylcelecoxib alleviated NK and T-cell exhaustion in hepatocellular carcinoma via the gastrointestinal microbiota-AMPK-mTOR axis.
- Personalized neoantigen vaccine combined with PD-1 blockade increases CD8+ tissue-resident memory T-cell infiltration in preclinical hepatocellular carcinoma models.
- A Nomogram Based on MRI Visual Decision Tree to Evaluate Vascular Endothelial Growth Factor in Hepatocellular Carcinoma.
- Performance of contrast-enhanced ultrasound liver imaging reporting and data system for differentiation of patients at risk of hepatocellular carcinoma and liver metastasis.
Trials on ClinicalTrials.gov6
- Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT
- A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma
- A Trial of Cadonilimab Plus Regorafenib in Patients With Hepatocellular Carcinoma Who Failed Camrelizumab Combined With Apatinib
- A Real-world Study of Camrelizumab Combined With Apatinib Mesylate in Unresectable Hepatocellular Carcinoma
- Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma
- A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
Stomach cancer
胃癌Led 316 of 9,782 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (3.9%).
- Open trials led
- 17
- Research papers it led
- 316
- Trials it led
- 74
- Share of China's trials
- 5.1%
- Share of the world's papers
- 1.5%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Laparoscopic Spleen-Preserving Hilar Lymphadenectomy for Advanced Proximal Gastric Cancer Without Greater Curvature Invasion: Five-Year Outcomes From the Fuges-02 Randomized Clinical Trial.
- Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up.
- Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.
- Long-term oncological outcomes of indocyanine green fluorescence imaging-guided laparoscopic lymphadenectomy for gastric cancer: 5-year outcomes from the FUGES-012 randomized clinical trial.
- Safety and efficacy of indocyanine green-guided laparoscopic lymphadenectomy for locally advanced gastric cancer: The CLASS-11 clinical trials.
Trials on ClinicalTrials.gov6
- Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer
- Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
- Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma
- Safety Comparison of Total Laparoscopic Proximal Gastrectomy With or Without Preservation of the Celiac Branch of the Vagus Nerve for Early Upper Gastric Cancer: A Randomized Controlled Clinical Trial
- Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Extended Lymphadenectomy Beyond D2 for Locally Advanced Gastric Cancer (FUGES-30)
- Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer
Retinoblastoma
视网膜母细胞瘤Led 4 of 301 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Identification of the shared gene signatures in retinoblastoma and osteosarcoma by machine learning.
- Construction of a Functional Nucleic Acid-Based Artificial Vesicle-Encapsulated Composite Nanoparticle and Its Application in Retinoblastoma-Targeted Theranostics.
- Carboplatin-loaded surface modified-PLGA nanoparticles confer sustained inhibitory effect against retinoblastoma cell in vitro.
- Circular RNA circ-FAM158A promotes retinoblastoma progression by regulating miR-138-5p/SLC7A5 axis.
Osteosarcoma
骨肉瘤Led 20 of 2,257 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 20
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Using machine learning techniques predicts prognosis of patients with Ewing sarcoma.
- A Case of Pancreatic Ewing Sarcoma.
- The tumor immune microenvironment and immune-related signature predict the chemotherapy response in patients with osteosarcoma.
- Licochalcone B targets neural cell adhesion molecule 1 to inhibit osteosarcoma progression and ferroptosis resistance via extracellular signal-regulated kinase 5 and nuclear factor kappa B pathways.
- The integrin α2-osteoclast axis: a key driver of bone destruction and therapeutic target in osteosarcoma.
Gastrointestinal stromal tumour
胃肠道间质瘤Led 18 of 523 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.3%).
- Open trials led
- 2
- Research papers it led
- 18
- Trials it led
- 4
- Share of China's trials
- 5.4%
- Share of the world's papers
- 1.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Prediction of the mitotic index and preoperative risk stratification of gastrointestinal stromal tumors with CT radiomic features.
- Prediction of recurrence-free survival and adjuvant therapy benefit in patients with gastrointestinal stromal tumors based on radiomics features.
- Gastrointestinal Bleeding in Small Intestinal Stromal Tumors: A Clinicopathological and Survival Analysis.
- Comparative efficacy of neoadjuvant imatinib therapy in gastric versus rectal gastrointestinal stromal tumors: a two-center retrospective cohort study.
- A novel prognostic system for locally advanced gastrointestinal stromal tumors after neoadjuvant imatinib therapy based on the metro-ticket paradigm: a retrospective dual-center study.
Trials on ClinicalTrials.gov6
- A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
- Comparison of Tumor Efficacy Safety in Laparoscopic Resection of Gastrointestinal Stromal Tumors Between Favorable and Unfavorable Site
- Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
- Development and External Validation of a Prognostic Model for DFS After Curative Resection of Duodenal GIST
- Preoperative Imatinib Mesylate Combined With Rectal-sparing Surgery in Patients With c-KIT Gene-mutant Rectal GIST
- A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Neuroblastoma
神经母细胞瘤Led 15 of 1,132 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 15
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- DDX3X promotes ILF3 stability to accelerate neuroblastoma progression via M2 macrophage polarization.
- Precision prognostication in neuroblastomas via clinically validated E2F activity signatures.
- Tyramine-enzyme conjugate repeats for an interdigitated capacitance immunosensing array in the detection of neuroblastoma biomarker neuron-specific enolase.
- Correlation of BARD1 gene polymorphisms with risk of neuroblastoma: a meta-analysis.
- LINC00460 promotes neuroblastoma tumorigenesis and cisplatin resistance by targeting miR-149-5p/DLL1 axis and activating Notch pathway in vitro and in vivo.
Ewing sarcoma
尤文肉瘤Led 2 of 163 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.6%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Multiple myeloma
多发性骨髓瘤Led 28 of 1,676 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.8%).
- Open trials led
- 1
- Research papers it led
- 28
- Trials it led
- 1
- Share of China's trials
- 0.2%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Early daratumumab-based therapy demonstrates significant effectiveness in patients with relapsed and refractory multiple myeloma: a real-world retrospective investigation.
- The value of multiparametric functional MRI histogram features in assessing multiple myeloma activity.
- Analysis of early efficacy and immune reconstitution after autologous hematopoietic stem cell transplantation in multiple myeloma.
- [68Ga]Pentixafor PET/CT for staging and prognostic assessment of newly diagnosed multiple myeloma: comparison to [18F]FDG PET/CT.
- Multiple myeloma identified within the same site of the mandible with medication-related osteonecrosis of jaw: An unusual case report.
Trials on ClinicalTrials.gov6
- Value of Chemokine Receptor CXCR4 Imaging for Diagnosis and Prognostic Evaluation in Lymphoproliferative Diseases
- A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma
- Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
- A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
B-cell acute lymphoblastic leukaemia (B-ALL)
B 细胞急性淋巴细胞白血病Led 5 of 225 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.9%).
- Open trials led
- 1
- Research papers it led
- 5
- Trials it led
- 2
- Share of China's trials
- 0.8%
- Share of the world's papers
- 0.5%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Philadelphia chromosome-positive or Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with multilineage involvement in pediatric patients: a report of two cases and literature review.
- UHRF1-mediated epigenetic reprogramming regulates glycolysis to promote progression of B-cell acute lymphoblastic leukemia.
- Stable isotope tracing reveals glucose metabolism characteristics of drug-resistant B-cell acute lymphoblastic leukemia.
- Prognostic significance and treatment strategies for IKZF1 deletion in pediatric B-cell precursor acute lymphoblastic leukemia.
- Long Non-Coding RNA RP11-252C15.1 Is a Potential Biomarker of Prognosis and Hallmark for Leukemogenesis in Children with B-Cell Precursor Acute Lymphoblastic Leukemia.
Trials on ClinicalTrials.gov6
- Clinical Study of Universal CD19 CAR-γδ T Cell Infusion in the Treatment of Relapsed/Refractory Acute B Lymphoblastic Leukemia
- Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
- Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- CART-19 Cells For R/R B-ALL
- A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL
Aplastic anaemia
再生障碍性贫血Led 4 of 412 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (17.2%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Unveiling Immunotherapy Evasion in Lung Cancer: The Role of Fanconi Anemia and Stemness Genes in Shaping an Immunosuppressive Microenvironment.
- The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
- UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT.
- Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia.
Beta thalassaemia
β 地中海贫血Led 14 of 312 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.9%).
- Open trials led
- 0
- Research papers it led
- 14
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.8%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Abnormal regulation of microRNAs and related genes in pediatric β-thalassemia.
- Comprehensive regulation of γ-globin expression by epigenetic modifications and protein post-translational modifications.
- Fujian Province β-Thalassemia: A Molecular and Hematological Study in Southeastern China.
- Upregulation of miR-17-3p is associated with HbF in patients with β-thalassemia and induces γ-globin expression by targeting BCL11A.
- First clinical and pedigree study of rare HBB: c.316-90 A > G variant in β-globin gene in Chinese population using third-generation sequencing.
Haemophilia A
血友病 ALed 8 of 272 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (15.8%).
- Open trials led
- 0
- Research papers it led
- 8
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Standard dose and low-dose rituximab combined with glucocorticoids and cyclophosphamide in the treatment of acquired haemophilia A.
- Development and validation of an innovative approach to estimating FVIII levels and designing personalised doses in the prophylactic treatment of haemophilia A: based on the principle of the two-compartment model.
- Perioperative Management of Hemophilia A Patients Undergoing Cardiac Surgery: A Literature Review of Published Cases.
- Impacts of the COVID-19 pandemic on pediatric and adult patients with hemophilia.
- Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.
Trials on ClinicalTrials.gov6
- A Clinical Study to Evaluate the Effects of NXT007 Compared to Emicizumab Prophylaxis in People With Hemophilia A
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
- Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
- Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products
- A Study of Adynovate in Previously Treated Chinese Teenagers and Adults With Severe Hemophilia A
- Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
Fanconi anaemia
范可尼贫血Led 3 of 68 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.8%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Unveiling Immunotherapy Evasion in Lung Cancer: The Role of Fanconi Anemia and Stemness Genes in Shaping an Immunosuppressive Microenvironment.
- The enrichment of Fanconi anemia/homologous recombination pathway aberrations in ATM/ATR-mutated NSCLC was accompanied by unique molecular features and poor prognosis.
- UBE2T regulates FANCI monoubiquitination to promote NSCLC progression by activating EMT.
Neuromyelitis optica spectrum disorder (NMOSD)
视神经脊髓炎谱系疾病Led 6 of 485 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.5%).
- Open trials led
- 0
- Research papers it led
- 6
- Trials it led
- 1
- Share of China's trials
- 1.3%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder.
- Dual BLyS/APRIL targeted therapy with telitacicept in rituximab-refractory SLE-associated neuromyelitis optica spectrum disorder: a case report.
- Characteristics of recurrence in area postrema-onset NMO spectrum disorder - a retrospective cohort study.
- The relationship between plasma prolactin levels and clinical manifestations with neuromyelitis optica spectrum disorders.
- Update on aquaporin-4 antibody detection: the early diagnosis of neuromyelitis optica spectrum disorders.
Trials on ClinicalTrials.gov4
- A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
- An Diagnostic Cohort on AQP4-Immunoglobulin G Detection Kit
- A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
- A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders
Myasthenia gravis
重症肌无力Led 3 of 499 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (6.6%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.1%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Impacts of tacrolimus and glucocorticoids on peripheral blood T and B lymphocyte subsets in myasthenia gravis.
- Delving into immune modulation: thymectomy in myasthenia gravis.
- Long non-coding RNA growth arrest specific 5 regulates the T helper 17/regulatory T balance by targeting miR-23a in myasthenia gravis.
Trials on ClinicalTrials.gov6
- Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
- A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases
- A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
- A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC in Adults With Ocular Myasthenia Gravis
Moyamoya disease
烟雾病Led 4 of 356 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (19.9%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Neurite orientation dispersion and density imaging reveals microstructural damage in moyamoya disease: a study based on tract- and gray-based spatial statistics.
- Clinical features, surgical treatment, and long-term outcomes of moyamoya disease in a single institution of Fujian, Southeast China: A retrospective study.
- Assessment of bypass patency using transcranial Doppler sonography: correlations with computerized tomography angiography findings in patients with moyamoya disease.
- Research progress on postoperative transient neurological dysfunction in pediatric and adult patients with moyamoya disease after revascularization surgery.
Trials on ClinicalTrials.gov1
Wilson disease
肝豆状核变性(Wilson 病)Led 4 of 201 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.5%).
- Open trials led
- 1
- Research papers it led
- 4
- Trials it led
- 1
- Share of China's trials
- 6.2%
- Share of the world's papers
- 0.6%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Reversible Diffusion-Weighted Imaging High Intensity Signal in Wilson Disease.
- Higher Concentration of Plasma Glial Fibrillary Acidic Protein in Wilson Disease Patients with Neurological Manifestations.
- Development of a gastrointestinal-restricted cellulose-based copper sequestrant: potential application in treating Wilson's disease.
- Altered cortical functional networks in Wilson's Disease: A resting-state electroencephalogram study.
Trials on ClinicalTrials.gov1
Biliary atresia
胆道闭锁Led 5 of 214 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.8%).
- Open trials led
- 0
- Research papers it led
- 5
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.7%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Prenatal Ultrasound Features of Biliary Atresia: Diagnostic Significance of Abnormal Gallbladder Size and Hepatic Hilar Cyst.
- Correlation analyses of ultrasonographic and histopathological characteristics of porta hepatis lymph nodes in biliary atresia.
- Gamma-Glutamyl Transferase Combined With Conventional Ultrasound Features in Diagnosing Biliary Atresia: A Two-Center Retrospective Analysis.
- Performance of two-dimensional shear wave elastography for detecting advanced liver fibrosis and cirrhosis in patients with biliary atresia: a systematic review and meta-analysis.
- The diagnostic performance of ultrasound elastography for biliary atresia: A meta-analysis.
Anti-NMDA receptor encephalitis
抗 NMDA 受体脑炎Led 2 of 264 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.2%).
- Open trials led
- 0
- Research papers it led
- 2
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led2
Idiopathic pulmonary fibrosis
特发性肺纤维化Led 9 of 989 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (4.3%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- A retrospective study of combination therapy with glucocorticoids and pirfenidone for PD-1 inhibitor-related immune pneumonitis.
- Molecular subtyping and prognostic evaluation in idiopathic pulmonary fibrosis: a focus on mechanical-related genes.
- Targeting insulin-like growth factor 1 signaling with Linsitinib to modulate fibroblast plasticity and attenuate pulmonary fibrosis.
- Multi-Omics Analysis Links Mitochondrial-Related Genes to Idiopathic Pulmonary Fibrosis and In Vivo Transcriptome Validation.
- Diagnostic and predictive values of m5C‑associated genes in idiopathic pulmonary fibrosis.
Amyotrophic lateral sclerosis
肌萎缩侧索硬化症Led 18 of 779 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (8.3%).
- Open trials led
- 1
- Research papers it led
- 18
- Trials it led
- 1
- Share of China's trials
- 1.8%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Biomarker profile of a Chinese ALS cohort: A comprehensive clinical-biomarkers-imaging analysis.
- Immune checkpoint changes correlate with the progression and prognosis of amyotrophic lateral sclerosis.
- Associations of cachexia and frailty with amyotrophic lateral sclerosis.
- Detection of pTDP-43 via routine muscle biopsy: A promising diagnostic biomarker for amyotrophic lateral sclerosis.
- Dynamic Changes in Functional Network Connectivity Involving Amyotrophic Lateral Sclerosis and Its Correlation With Disease Severity.
Trials on ClinicalTrials.gov4
- A Registered Cohort Study on Amyotrophic Lateral Sclerosis
- A Phase Ⅰ/Ⅱa Study of SNUG01 in Adult Subjects With ALS
- An IIT Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of a Single Intrathecal Injection of SNUG01 in Patients with Amyotrophic Lateral Sclerosis
- An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS
Spinal muscular atrophy
脊髓性肌萎缩症Led 0 of 55 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (29.1%).
- Open trials led
- 1
- Research papers it led
- 0
- Trials it led
- 2
- Share of China's trials
- 6.7%
- Share of the world's papers
- 0.0%
Duchenne muscular dystrophy
杜氏肌营养不良Led 6 of 213 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (10.8%).
- Open trials led
- 1
- Research papers it led
- 6
- Trials it led
- 1
- Share of China's trials
- 5.0%
- Share of the world's papers
- 0.2%
Over half of these papers are lab or animal studies.
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Quantitative muscle ultrasound in children with Duchenne muscular dystrophy: Comparing to magnetic resonance imaging.
- Adenine base editing-mediated exon skipping restores dystrophin in humanized Duchenne mouse model.
- enOsCas12f1-mediated exon skipping for Duchenne muscular dystrophy therapy in humanized mouse model.
- CRISPR/Cas9-based genome editing for the modification of multiple duplications that cause Duchenne muscular dystrophy.
- Generation and characterization of an induced pluripotent stem cell line (FJMUNi001-A) from a patient with Duchenne muscular dystrophy carrying c.4518 + 512 T > A variant in the DMD gene.
Behçet disease
白塞病Led 3 of 245 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (22.9%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Specific plasma metabolite profile in intestinal Behçet's syndrome.
- Association of CDK6 gene polymorphisms with Behcet's disease in a Han Chinese population.
- miR-141-3p attenuates RSL3-induced ferroptosis and intestinal epithelial-mesenchymal transition via directly inhabits ZEB1 in intestinal Behçet's syndrome.
IgA nephropathy
IgA 肾病Led 7 of 736 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (9.4%).
- Open trials led
- 0
- Research papers it led
- 7
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- Changes in the spectrum of kidney diseases: a 14-year single-center retrospective renal biopsy study from southeast China.
- Association of time-averaged serum uric acid level with clinicopathological information and long-term outcomes in patients with IgA nephropathy.
- Clinicopathologic features and long-term prognosis of hepatitis B virus-associated glomerulonephritis: a retrospective cohort study.
- SOCS1 improves abnormal IgA galactosylation in IgA nephropathy by regulating the TLR9/MyD88 pathway.
- KLF15 deficiency contributes complement activation and podocyte injury in IgA nephropathy via regulating p300/ NF-κB axis.
Trials on ClinicalTrials.gov1
Primary biliary cholangitis
原发性胆汁性胆管炎Led 4 of 300 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (12.0%).
- Open trials led
- 0
- Research papers it led
- 4
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.4%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led4
- Clinically significant portal hypertension in patients with primary biliary cholangitis: Clinicopathological features and prognostic value.
- Optimal drug regimens for improving ALP biochemical levels in patients with primary biliary cholangitis refractory to UDCA: a systematic review and Bayesian network meta-analysis.
- The causal relationship between inflammatory bowel disease and primary biliary cholangitis: A bidirectional two-sample Mendelian randomization study.
- The latest research trends in primary biliary cholangitis: a bibliometric analysis.
Trials on ClinicalTrials.gov3
- A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA
- Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis
Primary sclerosing cholangitis
原发性硬化性胆管炎Led 3 of 100 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (7.0%).
- Open trials led
- 0
- Research papers it led
- 3
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 0.3%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led3
- Clinical Impact of Primary Sclerosing Cholangitis on Outcomes of Inflammatory Bowel Disease Hospitalization: A Propensity Score Matching Analysis of the Nationwide Inpatient Sample.
- Risk of hepato-pancreato-biliary cancer is increased by primary sclerosing cholangitis in patients with inflammatory bowel disease: A population-based cohort study.
- Investigating the shared genetic architecture between primary sclerosing cholangitis and inflammatory bowel diseases: a Mendelian randomization study.
Hirschsprung disease
先天性巨结肠Led 9 of 161 English-language PubMed papers from mainland China, 2021–2025 (first or last author lists this institution first).
The bar compares it with the institution that has the largest share (13.0%).
- Open trials led
- 0
- Research papers it led
- 9
- Trials it led
- 0
- Share of China's trials
- 0.0%
- Share of the world's papers
- 1.2%
Hospitals counted here
Papers led, 2021–2025. Provincial and city hospitals with teaching links are not grouped.
Papers it led5
- 10-year experience with single-site laparoscopic-assisted Soave operation for Hirschsprung disease.
- Laparoscopic-assisted Soave procedure for Hirschsprung disease: 10-year experience with 106 cases.
- Clinical Efficacy of an Indwelling Transanal Tube for the Prevention of Anastomotic Leakage After Hirschsprung's Disease: A Single Center Experience with Chinese Patients.
- General versus general anaesthesia combined with caudal block in laparoscopic-assisted Soave pull-through of Hirschsprung disease: a retrospective study.
- Tracing the enteric neural crest cell pathway from origin to colonization: insights into Hirschsprung's disease.